This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A One-Year Double-Blind Comparison in Multiple Episode Schizophrenics

Frederic Quitkin, MD; Arthur Rifkin, MD; John Kane, MD; Jorge R. Ramos-Lorenzi, MD; Donald F. Klein, MD

Arch Gen Psychiatry. 1978;35(7):889-892.

Abstract
• Sixty patients meeting the criteria established for schizophrenia who attained a clinical plateau following hospital discharge were randomized to receive for one year either penfluridol, 20 to 160 mg orally once each week, or fluphenazine decanoate, 0.5 to 4 ml every two weeks.

The relapse rate for both treatments was low and equal. The rate of recurrence of psychosis for patients receiving penfluridol was 7% and for those receiving fluphenazine decanoate 10%. A retrospective comparison of the penfluridol group was made to a similar group of patients assigned to placebo in an earlier study. Placebo-treated patients had a relapse rate of 68%. Penfluridol patients had statistically fewer psychotic relapses.

Questions about the possible carcinogenicity of penfluridol in animals will have to be resolved before it can be widely used. This study demonstrates the feasibility of using an oral, longacting antipsychotic agent. It would be a useful psychopharmacologic addition in the treatment of outpatient schizophrenics.

Author Affiliations
From New York State Psychiatric Institute and the College of Physicians and Surgeons, Columbia University, New York (Drs Quitkin, Rifkin, and Klein), and Long Island Jewish-Hillside Medical Center, Glen Oaks, NY (Drs Kane and Ramos-Lorenzi).

Footnotes
Accepted for publication July 25, 1977.

Reprint requests to New York State Psychiatric Institute, 722 W 168th St, New York, NY 10032 (Dr Quitkin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT | FULL TEXT  

Compliance With Medication Regimens for Mental and Physical Disorders
Cramer and Rosenheck
Psychiatr. Serv. 1998;49:196-201.
ABSTRACT | FULL TEXT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics: I. Preliminary Results for Relapse Rates
Kane et al.
Arch Gen Psychiatry 1983;40:893-896.
ABSTRACT  

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane et al.
Arch Gen Psychiatry 1982;39:70-73.
ABSTRACT  

'Revealed' Depression and Drug Treatment for Schizophrenia
Knights and Hirsch
Arch Gen Psychiatry 1981;38:806-811.
ABSTRACT